Cited by 1,128Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and TreatmentCutaneous lymphoproliferative disorders research

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

Open access

Advani, Ranjana H., Buggy, Joseph J., Sharman, Jeff P., Smith, Sonali M., Boyd, Thomas E., Grant, Barbara, Kolibaba, Kathryn S., Furman, Richard R., Rodriguez, Sara, Chang, Betty Y., Sukbuntherng, Juthamas, Izumi, Raquel, Hamdy, Ahmed, Hedrick, Eric, Fowler, Nathan H.·2013·Journal of Clinical Oncology

DOI 10.1200/jco.2012.42.7906PMC PMC5505166

Open this paper in CoChat — free account Open PDF

Abstract

Purpose: Survival and progression of mature B-cell malignancies depend on signals from the B-cell antigen receptor, and Bruton tyrosine kinase (BTK) is a critical signaling kinase in this pathway. We evaluated ibrutinib (PCI-32765), a small-molecule irreversible inhibitor of BTK, in patients with B-cell malignancies. Patients and Methods: Patients with relapsed or refractory B-cell lymphoma and chronic lymphocytic leukemia received escalating oral doses of ibrutinib. Two schedules were evaluated: one, 28 days on, 7 days off; and two, once-daily continuous dosing. Occupancy of BTK by ibrutinib in peripheral blood was monitored using a fluorescent affinity probe. Dose escalation proceeded until either the maximum-tolerated dose (MTD) was achieved or, in the absence of MTD, until three dose levels above full BTK occupancy by ibrutinib. Response was evaluated every two cycles. Results: Fifty-six patients with a variety of B-cell malignancies were treated over seven cohorts. Most adverse events were grade 1 and 2 in severity and self-limited. Dose-limiting events were not observed, even with prolonged dosing. Full occupancy of the BTK active site occurred at 2.5 mg/kg per day, and dose escalation continued to 12.5 mg/kg per day without reaching MTD. Pharmacokinetic data indicated rapid absorption and elimination, yet BTK occupancy was maintained for at least 24 hours, consistent with the irreversible mechanism. Objective response rate in 50 evaluable patients was 60%, including complete response of 16%. Median progression-free survival in all patients was 13.6 months. Conclusion: Ibrutinib, a novel BTK-targeting inhibitor, is well tolerated, with substantial activity across B-cell histologies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.2012.42.7906

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Revised response criteria for malignant lymphoma.
Cheson, B. D., Pfistner, B., Juweid, M., Gascoyne, R., Specht, L., Horning, S., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,537
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
Hallek, M. J., Cheson, B. D., Catovsky, D., Caligaris‐Cappio, F., Dighiero, G., Döhner, H., Hillmen, P., Keating, M. J., Montserrat, E., Rai, K. R., et al. (2008) · Blood · doi:10.1182/blood-2007-06-093906 · Cited by 3,782
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
Davis, R. E., Ngo, V. N., Lenz, G., Tolar, P., Young, R. M., Romesser, P. B., Kohlhammer, H., Lamy, L., Zhao, H., Yang, Y., et al. (2010) · Nature · doi:10.1038/nature08638 · Cited by 1,651
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561
Self-citation
Mechanisms of B-cell lymphoma pathogenesis
Küppers, R. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1589 · Cited by 966
The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia
Herishanu, Y., Pérez‐Galán, P., Liu, D., Biancotto, A., Pittaluga, S., Vire, B., Gibellini, F., Njuguna, N., Lee, E., Stennett, L. S., et al. (2010) · Blood · doi:10.1182/blood-2010-05-284984 · Cited by 817
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
Friedberg, J. W., Sharman, J. P., Sweetenham, J. W., Johnston, P. B., Vose, J. M., LaCasce, A. S., Schaefer-Cutillo, J., de Vos, S., Sinha, R., Leonard, J. P., et al. (2009) · Blood · doi:10.1182/blood-2009-08-236471 · Cited by 747
Self-citation
Regulation of B-cell fate by antigen-receptor signals
Niiro, H., & Clark, E. A. (2002) · Nature reviews. Immunology · doi:10.1038/nri955 · Cited by 653

Flagged first, then by citations

Show all 32 references

Research works printed but not linked: 1

Chang BY, 2011, Blood, 118

Sorted by citations

Items 301–400 of 1,001

Current therapeutic strategies and perspectives in refractory ITP: What have we learned recently?
Lv, Y., Shi, H., Liu, H., & Zhou, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.953716 · Cited by 48
“BTK inhibitor is of high clinical value in Bcell malignancies and has potential clinical applications in autoimmune diseases (46, 47).”
Background
The complex interplay between cell-intrinsic and cell-extrinsic factors driving the evolution of chronic lymphocytic leukemia
Sutton, L., & Rosenquist, R. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.04.009 · Cited by 47
The phosphatidylinositol-3-kinase inhibitor NVP-BKM120 overcomes resistance signals derived from microenvironment by regulating the Akt/FoxO3a/Bim axis in chronic lymphocytic leukemia cells
Rosich, L., Saborit-Villarroya, I., Lopez-Guerra, M., Xargay‐Torrent, S., Montraveta, A., Aymerich, M., Villamor, N., Campo, E., Pérez‐Galán, P., Roué, G., et al. (2013) · Haematologica · doi:10.3324/haematol.2013.088849 · Cited by 45
Management of chronic lymphocytic leukemia
Ghia, P., & Hallek, M. J. (2014) · Haematologica · doi:10.3324/haematol.2013.096107 · Cited by 46
“Results on clinical agents in refractory CLL patients have been published or presented in a preliminary form and are very encouraging, suggesting that we will see big changes in our armamentarium of CLL therapeutics over the next few months.(68,69) This optimism is supported by previous phase II studies of ibrutinib i…”
Result
CD79B limits response of diffuse large B cell lymphoma to ibrutinib
Kim, J. H., Kim, W. S., Ryu, K. J., Kim, S. J., & Park, C. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1113276 · Cited by 45
“[11–15] Recent preliminary studies have disclosed therapeutic activity of ibrutinib in some ABC-DLBCL, but not GCB-DLBCL.[16] Despite its activity, however, 430% patients with MCL display primary resistance and frequent disease progression during ibrutinib treatment.”
Background
CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia
Bo, M. D., Bulian, P., Bomben, R., Zucchetto, A., Rossi, F. M., Pozzo, F., Tissino, E., Benedetti, D., Bittolo, T., Nanni, P., et al. (2016) · Leukemia · doi:10.1038/leu.2016.88 · Cited by 45
Diffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives
Chiappella, A., Castellino, A., Nicolosi, M., Santambrogio, E., & Vitolo, U. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1305264 · Cited by 46
“[72] conducted a trial with Ibrutinib in 56 patients, with a median age of 65 years (range 41–82) affected by R/R B-cell malignancies, among which 7 DLBCL patients, with promising results.”
Method
Dose reductions in ibrutinib therapy are not associated with inferior outcomes in patients with chronic lymphocytic leukemia (CLL)
Akhtar, O. S., Attwood, K. M., Lund, I., Hare, R. B., Hernandez‐Ilizaliturri, F. J., & Torka, P. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1554862 · Cited by 46
Differential impact of BTK active site inhibitors on the conformational state of full-length BTK
Joseph, R. E., Amatya, N., Fulton, D. B., Engen, J. R., Wales, T. E., & Andreotti, A. H. (2020) · eLife · doi:10.7554/elife.60470 · Cited by 47
“Ibrutinib levels in the serum peak 1–2 hr post-ingestion and return to basal levels after 3–4 hr (Advani et al., 2013).”
Background
HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma
Jacobson, C., Kopp, N., Layer, J. V., Redd, R. A., Tschuri, S., Haebe, S., van Bodegom, D., Bird, L., Christie, A. L., Christodoulou, A., et al. (2016) · Blood · doi:10.1182/blood-2016-04-711176 · Cited by 45
“The majority of MCLs have constitutive activation of the B-cell receptor (BCR) signaling pathway through the kinases Bruton tyrosine kinase (BTK), LYN, SYK, and downstream pathways, including MAPK and classical NF-kB.3,4 Inhibition of BTK with the smallmolecule inhibitor ibrutinib is an effective strategy in these MCL…”
Background
Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies
Hallek, M. J. (2013) · Hematology · doi:10.1182/asheducation-2013.1.138 · Cited by 46
Targeting of B‐cell receptor signalling in B‐cell malignancies
Jerkeman, M., Hallek, M. J., Dreyling, M. H., Thiéblemont, C., Kimby, E. K., & Staudt, L. M. (2017) · Journal of Internal Medicine · doi:10.1111/joim.12600 · Cited by 44
The effect of Bruton's tyrosine kinase ( BTK ) inhibitors on collagen‐induced platelet aggregation, BTK , and tyrosine kinase expressed in hepatocellular carcinoma ( TEC )
Chen, J., Kinoshita, T., Gururaja, T. L., Sukbuntherng, J., James, D. F., Lu, D., Whang, J. A., Versele, M., & Chang, B. Y. (2018) · European Journal Of Haematology · doi:10.1111/ejh.13148 · Cited by 46
Self-citation
Mantle cell lymphoma and its management: where are we now?
Ladha, A., Zhao, J., Epner, E. M., & Pu, J. J. (2019) · Experimental Hematology and Oncology · doi:10.1186/s40164-019-0126-0 · Cited by 44
“Bruton’s tyrosine kinase (BTK) inhibitors Early studies in relapsed setting showed that Ibrutinib, a Bruton’s tyrosine kinase inhibitor resulted in response rate and CR of 77% and 33% respectively [39].”
Background
A phase II study of Bruton’s tyrosine kinase inhibition for the prevention of anaphylaxis
Suresh, R. V., Dunnam, C., Vaidya, D. M., Wood, R. A., Bochner, B. S., MacGlashan, D. W., & Dispenza, M. C. (2023) · Journal of Clinical Investigation · doi:10.1172/jci172335 · Cited by 43
“The dose of acalabrutinib utilized in this trial, which is the FDA-approved dose for treating B cell malignancies, has been shown to result in 100% drug occupancy of BTK in peripheral blood mononuclear cells (15, 16).”
Ibrutinib for the Treatment of Mantle Cell Lymphoma
Herrera, A. F., & Jacobsen, E. D. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0010 · Cited by 43
“(10) [entire cohort] [entire cohort] 33% CR [entire cohort] 44% PR 11% SD”
BackgroundInfluential
Current Status of Bruton’s Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies
Aw, A., & Brown, J. R. (2017) · Drugs & Aging · doi:10.1007/s40266-017-0468-4 · Cited by 43
Auranofin Enhances Ibrutinib's Anticancer Activity in EGFR-Mutant Lung Adenocarcinoma
Hu, J., Zhang, H., Cao, M., Wang, L., Wu, S., & Fang, B. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1173 · Cited by 46
“In vitro drug sensitivity was determined using the sulforhodamine B assay, as we reported previously (38).”
BackgroundMethodInfluential
Covalent binders in drug discovery
Vasudevan, A., Argiriadi, M. A., Baranczak, A., Friedman, M., Gavrilyuk, J. I., Hobson, A. D., Hulce, J. J., Osman, S., & Wilson, N. S. (2019) · Progress in medicinal chemistry · doi:10.1016/bs.pmch.2018.12.002 · Cited by 43
Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib
Hopper, M. J., Gururaja, T. L., Kinoshita, T., Dean, J. P., Hill, R. J., & Mongan, A. M. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.262063 · Cited by 46
“1 hours after dosing, respectively (Advani et al., 2013; Byrd et al., 2016).”
BackgroundInfluential
Pathogenesis of chronic lymphocytic leukemia and the development of novel therapeutic strategies
Kikushige, Y. (2020) · Journal of the Japan Society of the Reticuloendothelial System · doi:10.3960/jslrt.20036 · Cited by 48
Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma
Hess, G., Keller, U. B., Scholz, C. W., Witzens‐Harig, M., Atta, J. A., Buske, C., Kirschey, S., Ruckes, C., Medler, C., van Oordt, C. W. M. D. H., et al. (2015) · Leukemia · doi:10.1038/leu.2015.60 · Cited by 42
The PI3K pathway: clinical inhibition in chronic lymphocytic leukemia
Brown, J. R. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.02.004 · Cited by 42
“This type of response was reported very early on from this study [17] but soon thereafter was seen also with the BTK inhibitor ibrutinib [18] and led to a revision of the response criteria such that this increase in lymphocyte count was not considered progressive disease.”
Result
Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib
Kazianka, L., Drucker, C., Skrabs, C., Thomas, W., Melchardt, T., Struve, S., Bergmann, M. M., Staber, P. B., Porpaczy, E. A., Einberger, C., et al. (2016) · Leukemia · doi:10.1038/leu.2016.316 · Cited by 43
A phase 1/2 trial of ibrutinib in combination with pembrolizumab in patients with mismatch repair proficient metastatic colorectal cancer
Kim, D. W., Tan, E. S., Zhou, J., Schell, M. J., Martinez, M., Yu, J. B., Carballido, E. M., Mehta, R. J., Strosberg, J., Imanirad, I., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01368-z · Cited by 44
A drive through cellular therapy for CLL in 2015: allogeneic cell transplantation and CARs
Mato, A. R., & Porter, D. L. (2015) · Blood · doi:10.1182/blood-2015-03-585091 · Cited by 41
Targeting the B-cell receptor signaling pathway in B lymphoid malignancies
Buchner, M., & Müschen, M. (2014) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000048 · Cited by 42
Role of MYD88 in lymphoplasmacytic lymphoma diagnosis and pathogenesis
Rossi, D. (2014) · Hematology · doi:10.1182/asheducation-2014.1.113 · Cited by 41
Neurological complications of new chemotherapy agents
Zukas, A. M., & Schiff, D. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox115 · Cited by 43
Inhibition of effector B cells by ibrutinib in systemic sclerosis
Einhaus, J. F., Pecher, A., Asteriti, E., Schmid, H., Secker, K.-A., Duerr‐Stoerzer, S., Keppeler, H., Klein, R., Schneidawind, C., Henes, J., et al. (2020) · Arthritis Research & Therapy · doi:10.1186/s13075-020-02153-8 · Cited by 42
“Consequently, ibrutinib was first tested in the context of B cell malignancies and proved effective in patients with relapsed or refractory non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, or Waldenström macroglobulinemia [16].”
Background
BCR pathway inhibition as therapy for chronic lymphocytic leukemia and lymphoplasmacytic lymphoma
Wiestner, A. U. (2014) · Hematology · doi:10.1182/asheducation-2014.1.125 · Cited by 41
Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia
Amin, N. A., Balasubramanian, S., Saiya-Cork, K., Shedden, K., Hu, N., & Malek, S. N. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2921 · Cited by 40
“Clin Cancer Res; 23(4) February 15, 2017 Clinical Cancer Research 1054”
BackgroundInfluential
Inhibiting Bruton’s Tyrosine Kinase in CLL and Other B-Cell Malignancies
Lucas, F. M., & Woyach, J. A. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00635-7 · Cited by 40
Bioanalysis of Ibrutinib and its Active Metabolite in Human Plasma: Selectivity Issue, Impact Assessment and Resolution
de Vries, R., Huang, M. Q., Bode, N., Jejurkar, P., de Jong, J., Sukbuntherng, J., Sips, L., Weng, N., Timmerman, P., & Verhaeghe, T. (2015) · Bioanalysis · doi:10.4155/bio.15.159 · Cited by 39
Self-citation
Risks and Benefits of Phase 1 Clinical Trial Participation
Mahipal, A., & Nguyen, D. (2014) · Cancer Control · doi:10.1177/107327481402100303 · Cited by 39
Myc enhances B-cell receptor signaling in precancerous B cells and confers resistance to Btk inhibition
Moyo, T. K., Wilson, C., Moore, D. J., & Eischen, C. M. (2017) · Oncogene · doi:10.1038/onc.2017.95 · Cited by 40
“Aberrant activation of BCR and PI3K/Akt signaling has been demonstrated in B-NHL.”
Influential
Optimizing Platelet GPVI Inhibition versus Haemostatic Impairment by the Btk Inhibitors Ibrutinib, Acalabrutinib, ONO/GS-4059, BGB-3111 and Evobrutinib
Denzinger, V., Busygina, K., Jamasbi, J., Pekrul, I., Spannagl, M., Weber, C., Lorenz, R. L., & Siess, W. (2019) · Thrombosis and Haemostasis · doi:10.1055/s-0039-1677744 · Cited by 40
SLAMF receptors negatively regulate B cell receptor signaling in chronic lymphocytic leukemia via recruitment of prohibitin-2
von Wenserski, L., Schultheiß, C., Bolz, S. N., Schliffke, S., Simnica, D., Willscher, E., Gerull, H., Wolters‐Eisfeld, G., Riecken, K., Fehse, B., et al. (2020) · Leukemia · doi:10.1038/s41375-020-01025-z · Cited by 42
Discovery of 1-Amino-1 H -imidazole-5-carboxamide Derivatives as Highly Selective, Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitors
Ma, C., Li, Q., Zhao, M., Fan, G., Zhao, J., Zhang, D., Yang, S., Zhang, S., Gao, D., Mao, L., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01559 · Cited by 39
Zanubrutinib for treatment‐naïve and relapsed/refractory chronic lymphocytic leukaemia: long‐term follow‐up of the phase I/II AU‐003 study
Cull, G., Burger, J. A., Opat, S., Gottlieb, D. J., Verner, E., Trotman, J., Marlton, P. V., Munoz, J. L., Johnston, P., Simpson, D., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17994 · Cited by 39
“At the recommended phase II dose (RP2D) of 160 mg twice daily, BTK exposure levels were ~eightfold higher than those observed for ibrutinib at 560 mg daily in blood and lymph node compartments.(6,7) In the first-in-human phase I/II AU-003 study (NCT02343120) in a cohort of 94 patients with CLL/SLL at a median follow-u…”
Background
Myeloid Cells as Targets for Therapy in Solid Tumors
Cotechini, T., Medler, T. R., & Coussens, L. M. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000132 · Cited by 40
Management of atrial fibrillation in patients taking targeted cancer therapies
Asnani, A. H., Manning, A., Mansour, M., Ruskin, J. N., Hochberg, E. P., & Ptaszek, L. M. (2017) · Cardio-Oncology · doi:10.1186/s40959-017-0021-y · Cited by 39
“In the initial clinical trials of ibrutinib, serial electrocardiographic studies were performed without any evidence of arrhythmia [16, 17].”
Background
Multidomain Control Over TEC Kinase Activation State Tunes the T Cell Response
Andreotti, A. H., Joseph, R. E., Conley, J. M., Iwasa, J., & Berg, L. J. (2018) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042617-053344 · Cited by 38
A Head-To-Head Phase III Study Comparing Zanubrutinib Versus Ibrutinib in Patients with Waldenström Macroglobulinemia
Tam, C. S. L., Leblond, V., Novotny, W. F., Owen, R. G., Tedeschi, A., Atwal, S. K., Cohen, A. C., Huang, J. Q., & Buske, C. (2018) · Future Oncology · doi:10.2217/fon-2018-0163 · Cited by 38
Btk Inhibitors as First Oral Atherothrombosis-Selective Antiplatelet Drugs?
Busygina, K., Denzinger, V., Bernlochner, I., Weber, C., Lorenz, R. L., & Siess, W. (2019) · Thrombosis and Haemostasis · doi:10.1055/s-0039-1687877 · Cited by 38
Bruton’s tyrosine kinase: an emerging targeted therapy in myeloid cells within the tumor microenvironment
Good, L., Benner, B. N., & Carson, W. E. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02908-5 · Cited by 39
“Furthermore, a phase II trial in refractory MCL patients reported a complete response in 40% of patients [73].”
BackgroundInfluential
BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD
Khouri, I. F., Wei, W., Korbling, M. J., Turturro, F., Ahmed, S., Alousi, A. M., Anderlini, P. N., Ciurea, S. O., Jabbour, E. J., Oran, B., et al. (2014) · Blood · doi:10.1182/blood-2014-07-587519 · Cited by 37
Blinatumomab for the treatment of B-cell lymphoma
Oak, E., & Bartlett, N. L. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1021415 · Cited by 37
“Ibrutinib, an inhibitor of Bruton’s tyrosine kinase, was recently approved for relapsed MCL and CLL/SLL and has shown clinical activity in preliminary reports in activated B-cell (ABC) DLBCL and FL [10-16].”
Background
MicroRNAs regulate key cell survival pathways and mediate chemosensitivity during progression of diffuse large B-cell lymphoma
Leivonen, S., Icay, K., Jäntti, K., Sirén, I., Liu, C., Alkodsi, A., Cervera, A., Ludvigsen, M., Hamilton-Dutoit, S. J., d’Amore, F., et al. (2017) · Blood Cancer Journal · doi:10.1038/s41408-017-0033-8 · Cited by 38
Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia
Stanchina, M., Montoya, S., Danilov, A. V., Castillo, J. J., Alencar, A. J., Chavez, J. C., Cheah, C. Y., CHIATTONE, C. S., Wang, Y., Thompson, M. C., et al. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00956-1 · Cited by 40
“Del(8p) results in haploinsufficiency of TNF ‐ related apoptosis ‐ mediated ligand receptor (TRAILR), which is hypothesized to result in insensitivity to TRAIL-induced apoptosis 5,92,93 .”
Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML
Wu, H., Hu, C., Wang, A., Weisberg, E., Wang, W., Chen, C., Zhao, Z., Yu, K., Liu, J., Wu, J., et al. (2015) · Leukemia · doi:10.1038/leu.2015.175 · Cited by 37
BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future
Spaargaren, M., de Rooij, M. F. M., Kater, A. P., & Eldering, E. (2014) · Oncogene · doi:10.1038/onc.2014.181 · Cited by 37
Immunohistochemical analysis indicates that the anatomical location of B-cell non-Hodgkin’s lymphoma is determined by differentially expressed chemokine receptors, sphingosine-1-phosphate receptors and integrins
Middle, S., Coupland, S. E., Taktak, A. F. G., Kidgell, V., Slupsky, J. R., Pettitt, A. R., & Till, K. J. (2015) · Experimental Hematology and Oncology · doi:10.1186/s40164-015-0004-3 · Cited by 35
“With regard to emerging therapies, drugs such as ibrutinib and idelalisib, which inhibit kinases involved in B-cell receptor signalling, have successfully been used in the treatment of lymphoma [44-46].”
Background
A Phase II Study of a Nonmyeloablative Allogeneic Stem Cell Transplant with Peritransplant Rituximab in Patients with B Cell Lymphoid Malignancies: Favorably Durable Event-Free Survival in Chemosensitive Patients
Sauter, C. S., Barker, J. N., Lechner, L., Zheng, J., Devlin, S. M., Papadopoulos, E. B., Perales, M., Jakubowski, A. A., Goldberg, J. D., Koehne, G., et al. (2013) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2013.11.029 · Cited by 36
“Given these findings, the negative prognostic impact of chemotherapy resistance must prompt careful consideration about additional chemotherapy regimens before RIC/NMA allo-SCT, especially considering the burgeoning development of highly active, and relatively nontoxic, targeted pathway inhibitors [45,46].”
Background
Recent developments in the chromatographic bioanalysis of approved kinase inhibitor drugs in oncology
Rood, J. J. M., Schellens, J. H. M., Beijnen, J. H., & Sparidans, R. W. (2016) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2016.06.037 · Cited by 37
Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma
Bennani, N. N., LaPlant, B. R., Ansell, S. M., Habermann, T. M., Inwards, D. J., Micallef, I. N., Johnston, P. B., Porrata, L. F., Colgan, J. P., Markovic, S. N., et al. (2017) · American Journal of Hematology · doi:10.1002/ajh.24671 · Cited by 36
Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration‐QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers
Becker, A. D., Martin, E. C., Mitchell, D. Y., Grenningloh, R., Bender, A. T., Laurent, J., Mackenzie, H. S., & Johne, A. (2019) · Clinical and Translational Science · doi:10.1111/cts.12713 · Cited by 36
“5 mg/kg/day; BTK occupancy was maintained for at least 24 hours, consistent with the irreversible mechanism.(20) Furthermore, following a single dose of CC-292, five of six healthy subjects had > 98% BTK occupancy ≤ 4 hours after administration, with complete or near-complete BTK occupancy sustained for 8–24 hours.”
Background
Ibrutinib
Charalambous, A., Schwarzbich, M., & Witzens‐Harig, M. (2018) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-91439-8_7 · Cited by 36
Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Kumar, S. K., Callander, N. S., Adekola, K., Anderson, L. D., Baljević, M., Baz, R., Campagnaro, E. L., Castillo, J. J., Costello, C. L., D'Angelo, C. R., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.0001 · Cited by 35
Ibrutinib in B lymphoid malignancies
Smith, M. R. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1067302 · Cited by 34
“1 Phase I A Phase I trial including patients with a range of relapsed B cell lymphomas showed high levels of activity (60% overall response rate (ORR) in 50 evaluable patients) across a broad range of histologies with good tolerance and no defined maximal tolerated dose [31].”
Background
Total Proteome Analysis Identifies Migration Defects as a Major Pathogenetic Factor in Immunoglobulin Heavy Chain Variable Region (IGHV)-unmutated Chronic Lymphocytic Leukemia
Eagle, G. L., Zhuang, J., Jenkins, R. E., Till, K. J., Jithesh, P. V., Lin, K., Johnson, G. G., Oates, M., Park, K., Kitteringham, N. R., et al. (2015) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m114.044479 · Cited by 36
Reduced intensity allogeneic stem cell transplantation for follicular lymphoma relapsing after an autologous transplant achieves durable long-term disease control: an analysis from the Lymphoma Working Party of the EBMT
Robinson, S. P., Boumendil, A., Finel, H., Schouten, H. C., Ehninger, G., Maertens, J. A., Crawley, C. R., Rambaldi, A., Russell, N. H., Anders, W., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw124 · Cited by 35
Decrease in total protein level of Bruton’s tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes
Cervantes-Gomez, F., Patel, V. M., Bose, P., Keating, M. J., & Gandhi, V. V. (2016) · Leukemia · doi:10.1038/leu.2016.129 · Cited by 35
CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphomas.
Onea, A. S., & Jazirehi, A. R. (2016) · PubMed Central · Cited by 35
Current Treatment of Chronic Lymphocytic Leukemia
Jamroziak, K., Puła, B., & Walewski, J. A. (2017) · Current Treatment Options in Oncology · doi:10.1007/s11864-017-0448-2 · Cited by 36
Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma
Battistello, E., Katanayeva, N., Dheilly, E., Tavernari, D., Collier, M. D., Bonsignore, L., Thome, M., Christie, A. L., Murakami, M. A., Michielin, O. A., et al. (2018) · Blood · doi:10.1182/blood-2017-10-809210 · Cited by 37
Simple determination of plasma ibrutinib concentration using high‐performance liquid chromatography
Yasu, T., Momo, K., Yasui, H., & Kuroda, S. (2018) · Biomedical Chromatography · doi:10.1002/bmc.4435 · Cited by 35
Three Newly Approved Drugs for Chronic Lymphocytic Leukemia: Incorporating Ibrutinib, Idelalisib, and Obinutuzumab into Clinical Practice
Sanford, D., Wierda, W. G., Burger, J. A., Keating, M. J., & O'Brien, S. M. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2015.02.019 · Cited by 35
Expression of Functional Sphingosine-1 Phosphate Receptor-1 Is Reduced by B Cell Receptor Signaling and Increased by Inhibition of PI3 Kinase δ but Not SYK or BTK in Chronic Lymphocytic Leukemia Cells
Till, K. J., Pettitt, A. R., & Slupsky, J. R. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402304 · Cited by 34
“These include idelalisib (CAL-101; GS-1101), ibrutinib (PCI-32765), and fostamatinib (R406), which inhibit, respectively, PI3Kd (20), Bruton’s tyrosine kinase (BTK) (21), and spleen tyrosine kinase (SYK), although fostamatinib has additional activity against some other kinases (22, 23).”
Background
Mantle cell lymphoma: state of the art.
Skarbnik, A. P. Z., & Goy, A. H. (2015) · PubMed · Cited by 34
Novel Self-Assembled Ibrutinib-Phospholipid Complex for Potently Peroral Delivery of Poorly Soluble Drugs with pH-Dependent Solubility
Qiu, Q., Lu, M., Li, C., Luo, X., Liu, X., Hu, L., Liu, M., Zheng, H., Zhang, H., Liu, M., et al. (2018) · AAPS PharmSciTech · doi:10.1208/s12249-018-1147-4 · Cited by 34
Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia
Hampel, P. J., Call, T. G., Rabe, K. G., Ding, W., Muchtar, E., Kenderian, S. S., Wang, Y., Leis, J. F., Witzig, T. E., Koehler, A. B., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0388 · Cited by 35
“Transient lymph node enlargement, often coinciding with drops in ALC, had been observed even later in the course of patients responding well to ibrutinib in an intermittent dosing protocol [26].”
Background
Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors
Fleming, M. R., Xiao, L., Jackson, K. D., Beckman, J. A., Barac, A., & Moslehi, J. J. (2021) · Circulation Research · doi:10.1161/circresaha.121.318259 · Cited by 36
Ibrutinib reverses IL-6-induced osimertinib resistance through inhibition of Laminin α5/FAK signaling
Li, L., Li, Z., Lu, C., Li, J., Zhang, K., Lin, C., Tang, X., Liu, Z., Zhang, Y., Han, R., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03111-7 · Cited by 34
Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers
Green, D. J., Frayo, S. L., Lin, Y., Hamlin, D. K., Fisher, D. R., Frost, S. H. L., Kenoyer, A. L., Hylarides, M. D., Gopal, A. K., Gooley, T. A., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0571 · Cited by 34
“An estimated 19,970 Americans died of Non-Hodgkin Lymphoma in 2015(1), despite the availability of modern immunochemotherapy regimens and the introduction of novel agents such as ibrutinib and idelalisib.(2,3) This statistic emphasizes the need for additional improvements in the therapeutic armamentarium for lymphomas.”
Background
Activating somatic mutations in diffuse large B-cell lymphomas: lessons from next generation sequencing and key elements in the precision medicine era
Bohers, É., Mareschal, S., Bertrand, P., Viailly, P., Dubois, S., Maingonnat, C., Ruminy, P., Tilly, H., & Jardin, F. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.941836 · Cited by 36
Novel Therapeutic Approaches to Allosensitization and Antibody-mediated Rejection
Jordan, S. C., Ammerman, N., Choi, J., Huang, E., Peng, A., Sethi, S., Najjar, R., Toyoda, M., Lim, K., Louie, S., et al. (2018) · Transplantation · doi:10.1097/tp.0000000000002462 · Cited by 33
Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma
He, Y., Li, J., Ding, N., Wang, X., Deng, L., Xie, Y., Ying, Z., Liu, W., Ping, L., Zhang, C., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1076-4 · Cited by 34
Noncovalent inhibitors reveal BTK gatekeeper and auto-inhibitory residues that control its transforming activity
Wang, S., Mondal, S., Zhao, C., Berishaj, M., Ghanakota, P., Batlevi, C. L., Doǧan, A., Seshan, V., Abel, R., Green, M. R., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.127566 · Cited by 33
The impact of activated p-AKT expression on clinical outcomes in diffuse large B-cell lymphoma: a clinicopathological study of 262 cases
Hong, J. Y., Hong, M. E., Choi, M., Kim, Y. S., Chang, W., Maeng, C. H., Park, S., Lee, S. J., Do, I., Jo, J.-S., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt530 · Cited by 32
“Hence, novel therapeutic approaches targeting diverse oncogenic signaling pathways in DLBCL are under investigation, including spleen tyrosine kinase inhibitors [3], Bruton’s tyrosine kinase inhibitor [4], protein kinase C β inhibitor [5], histone deacetylase inhibitor [6], mammalian target of rapamycin (mTOR) inhibit…”
Background
A method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds
Crochiere, M., Baloglu, E., Klebanov, B., Donovan, S., del Alamo, D., Lee, M. S., Kauffman, M., Shacham, S., & Landesman, Y. (2015) · OncoTarget · doi:10.18632/oncotarget.6495 · Cited by 40
“Similar occupancy assays have been developed for other drug-target interactions such as ibrutinib/Bruton tyrosine kinase [35, 36] and MDX-1106/programmed death-1 [37] proteins.”
Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia
Maddocks, K. J., & Jones, J. A. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.02.008 · Cited by 32
Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination?
Brown, J. R., Hallek, M. J., & Pagel, J. M. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_159018 · Cited by 38
Bruton’s tyrosine kinase inhibitors in B-cell lymphoma: current experience and future perspectives
Seiler, T., & Dreyling, M. H. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1349097 · Cited by 32
Recent survival trends in diffuse large B‐cell lymphoma––Have we made any progress beyond rituximab?
Epperla, N., Vaughn, J. L., Othus, M. K. D., Hallack-Neto, A. E., & Costa, L. J. (2020) · Cancer Medicine · doi:10.1002/cam4.3237 · Cited by 32
Idelalisib for the treatment of non-Hodgkin lymphoma
Graf, S. A., & Gopal, A. K. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1135130 · Cited by 33
“Ibrutinib has shown some activity in other subtypes of iB-NHL,[19] where its investigation is ongoing.”
Background
Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenstrom macroglobulinemia
de Rooij, M. F. M., Kuil, A., Kraan, W., Kersten, M. J., Treon, S. P., Pals, S. T., & Spaargaren, M. (2015) · Haematologica · doi:10.3324/haematol.2015.137265 · Cited by 32
“In these patients, the BCR signalosome inhibitors ibrutinib and idelalisib induce a rapid decrease in lymphadenopathy, accompanied by transient lymphocytosis.(6,9-11) In CLL and MCL, we have previously demonstrated that ibrutinib and idelalisib target BCR-controlled - and ibrutinib also chemokinecontrolled - integrin-…”
Background
Safety and tolerability of ibrutinib monotherapy in Japanese patients with relapsed/refractory B cell malignancies
Tobinai, K., Ogura, M., Ishizawa, K., Suzuki, T., Munakata, W., Uchida, T., Aoki, T., Morishita, T., Ushijima, Y., & Takahara, S. (2015) · International Journal of Hematology · doi:10.1007/s12185-015-1900-3 · Cited by 33
“However, patients receiving lower doses start losing full occupancy at 24 h, which is consistent with a previous report [14].”
BackgroundMethodResultInfluential
Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience
Castillo, J. J., Palomba, M. L., Advani, R. H., & Treon, S. P. (2016) · Therapeutic Advances in Hematology · doi:10.1177/2040620716654102 · Cited by 32
“The mean half-life is 2–3 hours, and there is no accumulation of ibrutinib after repeated daily dosing [Advani et al. 2013].”
BackgroundResultSelf-citation
B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies.
Koehrer, S., & Burger, J. A. (2016) · PubMed · Cited by 31
Treatment of splenic marginal zone lymphoma
Kalpadakis, C. H., Pangalis, G. A., Angelopoulou, M. K., & Vassilakopoulos, T. P. (2016) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2016.07.004 · Cited by 31
Bioanalysis of ibrutinib, and its dihydrodiol- and glutathione cycle metabolites by liquid chromatography-tandem mass spectrometry
Rood, J. J. M., Dormans, P. J. A., van Haren, M. J., Schellens, J. H. M., Beijnen, J. H., & Sparidans, R. W. (2018) · Journal of Chromatography B · doi:10.1016/j.jchromb.2018.05.011 · Cited by 31
“It is a first in class BTK inhibitor which inactivates the NFκB pathway, and is registered for mantle cell lymphoma, chronic lymphocytic leukemia, Waldenström's macroglobulinemia [3], marginal zone lymphoma, and chronic graft versus host disease [4].”
Background
Chronic Lymphocytic Leukaemia in 2020: the Future Has Arrived
Milne, K. M., Sturrock, B. R., & Chevassut, T. J. T. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-0893-0 · Cited by 33
Rationale for once-daily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma
Ou, Y. C., Tang, Z., Novotny, W. F., Cohen, A. C., Wang, K., Liu, L., Gao, Y., & Sahasranaman, S. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1929961 · Cited by 31
“Furthermore, Ctrough/IC50 (unbound) ratios for zanubrutinib following the QD dose are considerably higher than those of ibrutinib and acalabrutinib where compelling clinical efficacy data has been reported in patients with multiple B-cell malignancies [21,22].”
Background
Bruton's tyrosine kinase inhibition for the treatment of allergic disorders
Lin, E. V., Suresh, R. V., & Dispenza, M. C. (2024) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2024.03.002 · Cited by 30
“Ex vivo basophil activation has even been used as a surrogate marker for in vivo drug occupancy of BTK in peripheral blood mononuclear cells, including in ibrutinib’s phase 1 clinical trial 15 .”
Accelerated therapeutic progress in diffuse large B cell lymphoma
Cai, Q., Westin, J. R., Fu, K., Desai, M., Zhang, L., Huang, H., Jiang, W., Liang, R., Qian, Z., Champlin, R. E., et al. (2013) · Annals of Hematology · doi:10.1007/s00277-013-1979-7 · Cited by 30
Ibrutinib in chronic lymphocytic leukemia and B cell malignancies
Brown, J. R. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.803226 · Cited by 30
Using high-sensitivity sequencing for the detection of mutations in BTK and PLCγ2 genes in cellular and cell-free DNA and correlation with progression in patients treated with BTK inhibitors
Albitar, A., Ma, W., DeDios, I., Estella, J. J., Ahn, I. E., Farooqui, M. Z. H., Wiestner, A. U., & Albitar, M. X. (2017) · Oncotarget · doi:10.18632/oncotarget.15316 · Cited by 30
Disruption of Aneuploidy and Senescence Induced by Aurora Inhibition Promotes Intrinsic Apoptosis in Double Hit or Double Expressor Diffuse Large B-cell Lymphomas
Islam, S., Qi, W., Morales, C., Cooke, L. S., Spier, C. M., Weterings, E., & Mahadevan, D. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0089 · Cited by 29
“Moreover, HCK is a target of the BTK inhibitor ibrutinib (29, 46), providing a strong rationale for combination therapy of alisertib with ibrutinib to inhibit BCR signaling.”
Integrating novel drugs to chemoimmunotherapy in diffuse large B-cell lymphoma
Chiappella, A., Santambrogio, E., Castellino, A., Nicolosi, M., & Vitolo, U. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1350164 · Cited by 31
“Most adverse events were of grade 1–2 and self-limited and no dose-limiting toxicity occurred [36].”
Background

Authors: Advani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B., Kolibaba, K. S., Furman, R. R., Rodriguez, S., Chang, B. Y., Sukbuntherng, J., Izumi, R., Hamdy, A., Hedrick, E., & Fowler, N. H.
Affiliations: University of Vermont (US)
Corresponding author: Advani, Ranjana H.
ORCID: Advani, Ranjana H.
Sharman, Jeff P.
Smith, Sonali M.
Kolibaba, Kathryn S.
Furman, Richard R.
Chang, Betty Y.
Izumi, Raquel
Hamdy, Ahmed
Fowler, Nathan H.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2013-01-01
Volume: 31
Issue: 1
Pages: 88-94
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2012.42.7906
PMC: PMC5505166
OpenAlex: W2171771895
Cited by: 1,128
References: 32
Citations by year: 2026: 17 · 2025: 38 · 2024: 47 · 2023: 44 · 2022: 46 · 2021: 90 · 2020: 79 · 2019: 92 · 2018: 73 · 2017: 117 · 2016: 94 · 2015: 135 · 2014: 134 · 2013: 110
FWCI: 58.95
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Clinical Oncology (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Abbott Laboratories
GlaxoSmithKline
Gilead Sciences
Celgene
Genentech
Takeda Oncology
Pharmacyclics
National Cancer Institute (P30CA016672)
Topics: Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
Health Sciences › Medicine › Dermatology › Cutaneous lymphoproliferative disorders research
Keywords: ibrutinib, BTK inhibitors, relapsed/refractory B-cell malignancies, B-cell lymphoma, chronic lymphocytic leukemia, B cell receptor signaling, irreversible kinase inhibitors, BTK occupancy, dose-limiting toxicity, pharmacokinetics, progression-free survival
MeSH terms: Agammaglobulinaemia Tyrosine Kinase, Adenine, Administration, Oral, Adult, Aged, Aged, 80 and over, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Piperidines, Prognosis, Protein-Tyrosine Kinases, Pyrazoles, Pyrimidines, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Salvage Therapy, Drug Resistance, Neoplasm, Maximum Tolerated Dose, Protein Kinase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks